Anika Therapeutics (ANIK) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PolyPid (PYPD) has outperformed Anika Therapeutics (ANIK) over the past year, gaining 70.0% versus a gain of 33.9%. Over five years, ANIK leads with a -66.6% price change compared with -97.1% for PYPD. Anika Therapeutics is the larger company by market cap ($177.2 million vs $129.3 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIK | PYPD |
|---|---|---|
| Share price | $13.23 | $6.12 |
| Market cap | $177.22M | $129.29M |
| 1-day change | -0.38% | -6.56% |
| YTD return | +37.67% | +41.01% |
| 1-year return | +33.91% | +70.00% |
| 5-year return | -66.63% | -97.06% |
| Forward P/E | 13.23 | — |
| EPS (TTM) | $-0.03 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $112.82M | — |
| Revenue growth (YoY) | -5.91% | — |
| Net income (latest FY) | $-10.88M | $-34.17M |
| Gross margin | 56.56% | — |
| Operating margin | -9.80% | — |
| Net margin | -9.64% | — |
| 52-week high | $22.88 | $7.25 |
| 52-week low | $9.01 | $3.60 |
| Distance from 52-week high | -42.18% | -15.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +51.17% | +87.91% |
| Average volume | 105.68K | 148.00K |
| Shares outstanding | 13.40M | 21.13M |
| Employees | 235 | 69 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed ANIK by 36.1 percentage points over the past year.
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Health Care · Medical/Dental Instruments · 235 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
ANIK vs PYPD FAQ
Which is bigger, Anika Therapeutics or PolyPid?
Anika Therapeutics (ANIK) is larger, with a market capitalization of $177.22M compared with $129.29M for PolyPid (PYPD).
Which stock has performed better over the past year, ANIK or PYPD?
PYPD returned +70.00% over the past 12 months, compared with +33.91% for ANIK (price return, excluding dividends). Past performance does not predict future results.
Are Anika Therapeutics and PolyPid in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.